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The main stream of CD137 studies has been directed to the 
function of CD137 in CD8
+ T-cell immunity, including its an-
ti-tumor activity, and paradoxically the immunosuppressive 
activity of CD137, which proves to be of a great therapeutic 
potential for animal models of a variety of autoimmune and 
inflammatory diseases. Recent studies, however, add com-
plexes to the biology of CD137. Accumulating is evidence 
supporting that there exists a bidirectional signal trans-
duction pathway for the CD137 receptor and its ligand 
(CD137L). CD137/CD137L interactions are involved in the 
network of hematopoietic and nonhematopoietic cells in ad-
dition to the well characterized antigen-presenting cell-T cell 
interactions. Signaling through CD137L plays a critical role 
in the differentiation of myeloid cells and their cellular activ-
ities, suggesting that CD137L signals trigger and sustain 
inflammation. The overall consequence might be that the am-
plified inflammation by CD137L enhances the T-cell activity 
together with CD137 signals by upregulating costimulatory 
molecules, MHC molecules, cell adhesion molecules, cyto-
kines, and chemokines. Solving this outstanding issue is ur-
gent and will have an important clinical implication.
[Immune Network 2009;9(3):84-89]
INTRODUCTION
CD137 (also known as 4-1BB and TNFRSF9) is a prototype 
of costimulatory molecules for T cells. In particular, the inter-
a c t i o n s  b e t w e e n  C D 1 3 7  a n d  i t s  l i g a n d ,  C D 1 3 7  l i g a n d  
(CD137L; also known as 4-1BBL and TNFSF9), have been the 
m o s t  e x t e n s i v e l y  s t u d i e d  i n  C D 8
+ T  c e l l s  ( 1 - 3 ) .  L i g a t i o n  o f  
CD137 on CD8
+ T cells has been shown to markedly increase 
their survival, proliferation, and cytotoxic T lymphocyte (CTL) 
activities (4,5). In support of the importance of these inter-
actions in controlling CD8
+ T-cell function, anti-CD137 agonist 
monoclonal antibodies (mAbs) show a potent anti-tumor ac-
tivity  (6).  Paradoxically,  however,  stimulation  of  CD137  re-
sults in strong suppression of a variety of autoimmune or in-
flammatory diseases that are believed to be mediated mainly 
by CD4
+ T cells (7-19). Although there is no consensus on 
how  stimulation  of  CD137  inhibits  disease,  most  evidence 
suggests  that  its  effects  are  linked  to  decreased  activity  of 
pathogenic CD4
+ T cells. Therefore, signaling through CD137 
seems to be differentially regulated in CD4
+ T cells and CD8
+ 
T  cells.
    There is accumulating evidence showing that CD137/CD137L 
interactions are involved in inflammation (20,21). These inter-
actions may regulate inflammation by forming a complex net-
w o r k  c o n n e c t i n g  v a r i o u s  i m m u n e  c e l l s  a n d  n o n - i m m u n e  
cells.  In  this  brief  Review,  I  focus  on  the  role  of 
CD137/CD137L interactions in inflammation involving non-T 
cells,  including  granulocytes,  macrophage  and  endothelial 
c e l l s .  I  a l s o  d i s c u s s  h o w  s i g n a l i n g  t h r o u g h  C D 1 3 7  a n d  
CD137L result in inflammation, for which interference of the 
CD137 and CD137L pathway may provide a promising ther-
apeutic tool. Specific emphasis is put on the reverse signaling 
through CD137L that is thought to be linked to inflammation, 
even  though  this  area  is  not  broadly  studied.
EXPRESSION OF CD137 AND CD137L
High levels of CD137 are constitutively expressed on FoxP3
+ 
regulatory CD4
+ T cells (22,23). Expression levels of CD137 
on  other types of cells are none,  very low, or upregulated 
under  a  certain  condition  such  as inflammation.  Except for 
FoxP3
+ regulatory CD4
+ T cells, CD137 expression is inducible 
in lymphoid cells, including CD4
+ and CD8
+ T cells (1-3), nat-CD137/CD137L in Inflammation
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Table I. Expression profile of CD137 and CD137L
Cells expressing  Conditions of  Cells expressing  Conditions of CD137L 
CD137 CD137 expression CD137L expression
FoxP3
+ regulatory  Constitutive B cells Constitutive 
 CD4
+ T cells
DCs Inducible (T-cell activation signals) DCs Constitutive
Macrophages Inducible (T-cell activation signals) Macrophages Constitutive
Nuetrophils Inducible (inflammation stimuli) Neurtrophils Inducible (inflammation stimuli)
Mast cells Inducible (IgE) Mast cells Inducible (IgE)
CD4
+ T cells Inducible (T-cell activation signals) CD4
+ T cells Inducible (T-cell activation signals)
CD8
+ T cells Inducible (T-cell activation signals) CD4
+ T cells Inducible (T-cell activation signals)
CD8
+ T cells Inducible (T-cell activation signals) CD8
+ T cells Inducible (inflammation)
Endothelial cells Inducible (inflammation stimuli) Endothelial cells Inducible (inflammation stimuli)
Hemapoietic progenitors Constitutive Hemapoietic progenitors Constitutive
Fibroblasts Constitutive Fibroblasts Constitutive
Epithelial cells Inducible (hypoxia) Epithelial cells Inducible (hypoxia)
ural killer (NK) cells (24), and NKT cells (25). Among mye-
loid cells, neutrophils seem to constitutively express CD137, 
even  though  its  levels  are  low  on  the  cell  surface  (26,27). 
CD137 expression also is induced on other granulocytes such 
as mast cells (28) and eosinophils (29), and probably on in-
flammatory  macrophages  (30).  Interestingly,  CD137  is  in-
ducible on activated myeloid progenitors (31). Recent studies 
have  identified  expression  of  CD137  on  nonhematopoietic 
cells under disease conditions. These include endothelial cells, 
smooth  muscle  cells,  and  cardiac  myocytes  (20,32-34). 
    CD137L  is  constitutively  expressed  on  professional  anti-
gen-presenting cells (dendritic cells, monocyte/macrophages, 
and  B  cells)  and  upregulated  by  their  respective  activation 
stimuli (1-3). Like CD137, CD137L can be expressed in car-
diovascular  components  such  as  endothelial  cells,  smooth 
muscle cells, and cardiomyocytes (20,30,32,34,35). CD137L is 
detectable on hematopoietic stem cells (31,36,37). Our data 
have shown that CD137L expression is observed on various 
cell  types,  including  neutrophils  and  fibroblasts  (our  un-
published data). Expression profile of CD137/CD137L is sum-
marized  in  Table  I.
AMPLIFYING INFLAMMATORY RESPONSES 
THROUGH NON-T CELLS
There is evidence supporting that CD137/CD137L interactions 
participate in inflammation regulated by CD4
+ T cells. For ex-
ample, various inflammatory/autoimmune diseases (rheumatoid 
arthritis,  autoimmune  myocarditis,  herpetic  stromal  keratitis, 
allograft rejection, and graft-versus-host disease) have a mild-
er disease severity in the absence of CD137/CD137L interactions 
(11,21,30,38-42). However, it is not clear that the decreased in-
flammation  is  directly  attributable  to  blockade  of  the  CD137 
costimulatory  signal  transduction  pathway  in  CD4
+ T  c e l l s .  
Instead, CD137/CD137L interactions may control other steps of 
inflammatory processes rather than the activation phase of CD4
+ 
T  cells.  There  is  evidence  supporting  this  explanation.  First, 
CD4
+ T  c e l l s  o f  C D 1 3 7 - d e f i c i e n t  m i c e  s h o w  a  h y p e r -
responsiveness  to  antigens  (higher  proliferation  and  effector 
function) after antigen exposure (43). Second, CD137/CD137L 
interactions play a role in inflammation mediated by NK cells 
or NKT cells (25,44). Third, many studies suggest that signal-
ing via CD137 or CD137L is important for the differentiation 
and function of myeloid cells, including granulocytes, a major 
type  of  inflammation  players  (27-29,31,33,35). 
    CD137-deficient  neutrophils  are  defective  in  phagocytosis 
and ROS production, which are associated with the suscepti-
bility of CD137-deficient mice to Listeria monocytogenes in-
fections  (31).  The  defects  of  CD137-deficient  neutrophils 
might be due to their inability to deliver activation signals. 
Our  data  also  show  that  CD137-deficient  neutrophis  is  not 
able to infiltrate into the kidney after ischemia-reperfusion in-
jury (our unpublished data). Interestingly, despite their nor-
mal trafficking ability to the kidney that receives ischemia-re-
perfusion injury, CD137-sufficient neutrophils were not able 
to damage the kidney of CD137-deficient mice. These results 
indicate that signaling through CD137L on neutrophils is re-
quired for tissue damage mediated by neutrophils. It is possi-CD137/CD137L in Inflammation
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ble that the cytoplasmic domain of CD137L directly interacts 
with docking proteins in granules of neutrophils, resulting in 
degranulation, since proteins present on vesicles are shown 
to interact with the cytoplasmic domain of CD137L (HW Lee, 
personal  communication).  CD137-deficient  mast  cells  also 
show defects in signaling and degranulation triggered by IgE 
( 2 8 ) .  I n  c o n t r a s t  w i t h  t h e s e  p ro-inflammatory  properties  of 
CD137, CD137 on human neutrophils exhibits anti-inflamma-
tory  activity  by  abrogating  GM-CSF-mediated  anti-apoptosis 
(27). The reason why this difference occurs between human 
beings and mice is not known. In a similar context with neu-
trophils, activation of CD137 blocks GM-CSF or IL-5-mediated 
anti-apoptosis of eosinophils in patients with atopic dermatitis 
and extrinsic asthma (29). In contrast, CD137 is not expressed 
on eosinophils of patients with intrinsic asthma and idiopathic 
eosinophilia, therefore implicating that the absence of CD137 
signaling is associated with the accumulation of eosinophils. 
    Non-hematopoietic  cells  of  the  host  are  required  for  in-
duction  of  acute  lethality  by  anti-CD137  mAb  in  graft-ver-
sus-host disease (42), which indicates that signaling through 
CD137  in non-hematopoietic  cells play a critical role in in-
flammation induced by radiation and donor T cells. Indeed, 
CD137 expression is inducible by proinflammtory  cytokines 
in endothelial cells, and activation of CD137 induces adhesion 
molecule expression on their cell surface (20,21). Reverse sig-
naling through CD137L enhances monocyte migratory activity 
(20).  Therefore,  it  is  possible  that  signaling  through  either 
CD137  or  CD137L  guides  inflammatory  cells  to  the  in-
flammatory  site. 
    Considering that CD137/CD137L interactions are critical in 
the  induction  of  inflammation,  blocking  of  CD137/CD137L 
s h o u l d  i n h i b i t  t h e  p r o g r e s s i o n  o f  i n f l a m m a t o r y  d i s e a s e s .  I n  
fact,  this  is  the  case  (30,32,38,39,44).  However,  it  is  not 
known whether the blocking effects are due to the absence 
of signaling through CD137 or CD137L. As discussed in the 
next  section,  CD137L  reverse  signals  might  turn  out  to  be 
mainly  responsible  for  mediating  inflammation.
REVERSE SIGNALING, INFLAMMATION, AND 
DIFFERENTIATION OF MYELOID CELLS
It is now being accepted that many members of the TNF su-
perfamily,  including  CD137L,  have  a  reverse  signal  trans-
duction pathway (45). Accumulating evidence indicates that 
CD137L  signals  regulate  the  activity  of  professional  anti-
gen-presenting cells. For example, a recent study has demon-
strated  that  engagement  of  CD137L  induces  B  cell  pro-
liferation and immunoglobulin production (46). In particular, 
there  are  prominent  phenotypic  changes  in  monocytes  that 
receive CD137L stimulation, including cell proliferation, pro-
duction of proinflammatory cytokines and chemokines, and 
upregulation of cell adhesion molecules (thus enhancement 
of their infiltration capacity) (reviewed in Ref 47). Signaling 
via CD137L mediates similar activities in dendritic cells that 
are observable in monocytes: Cross-linking of CD137L enhan-
ces the expression of costimulatory ligands and MHC mole-
cules and the release of cytokines (47,48). In sum, CD137L 
signals on antigen-presenting cells act towards enforcing the 
adaptive  immune  response  and  inflammation. 
    Hematopoietic progenitor cells of CD137- or CD137L-defi-
cient mice have greater differentiation potency for myelopoi-
esis  (31).  This  is  due  to  the  absence  of  CD137L  signaling. 
In  a  similar  context,  CD137  on  osteoblasts  inhibits  M-CSF/ 
RANKL-mediated osteoclast differentiation by engaging CD137L 
on their cell surface (49). Some studies reported contradictory 
results by showing that engagement of CD137L induces pro-
liferation of hematopoietic progenitor cells and differentiation 
to  macrophages  (36,37).  The  physiological  meaning  under-
lying  these  observations  is  not  known  yet.
    Evidence barely exists that signaling through CD137L regu-
lates inflammation in vivo. As mentioned previously, our re-
constitution experiment indicates that effector mechanisms of 
neutrophils involve the CD137L but not CD137) signal trans-
duction  pathway  in  ischemia-reperfusion  kidney  injury  (our 
unpublished data). Furthermore, we have demonstrated that 
specific  blocking  of  the  CD137L  signaling  pathway,  using 
TAT-CD137L  cytoplasmic  domain  fusion  protein  (which 
blocks  the  signal  transduction  delivered  by  endogenous 
CD137L), induces increased vascular permeability in vivo, a 
phenomenon which is observed in CD137-deficient mice and 
in mice that receive anti-CD137L mAb (our unpublished da-
ta). Therefore, it is now clear that signaling through CD137L 
i s  c r i t i c a l  i n  r e g u l a t i n g  i n f l a m m a t i o n  i n  v a r i o u s  w a y s .
    Molecules involved in the CD137L signal transduction path-
way  are  now  being  indentified.  Upregualtion  of  cytokines 
and cell adhesion molecules in monocytes after CD137L stim-
ulation  specifically  requires  AKT  and  mTOR/p70S6  kinase 
(50).  Preliminary  results  show  that  the  cytoplasmic  domain 
of  CD137L  bind  to  proteins  potentially  associated  with  de-
granulation and phosphorylation, indicating that the cytoplas-
mic  domain  of  CD137L  may  function  as  a  docking  partner 
of  granule  membrane  proteins  to  trigger  degranulation,  as CD137/CD137L in Inflammation
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Figure 1. A schematic diagram showing a bidirectional signal 
transduction of the CD137 and CD137L pathway.
well as form a complex with protein kinase to deliver down-
s t r e a m  s i g n a l s  l e a d i n g  t o  p r o d u c t i o n  o f  c y t o k i n e s  i n  g r a n -
ulocytes and monocytes (HW Lee, personal communication). 
A recent study has shown that CD137L forms a complex with 
TLRs and sustains TNF production by TLRs, independently of 
engagement  with  CD137  (51).
CONCLUSION REMARKS
Humanized  anti-CD137  mAb  is  in  Phase  II  clinical  trials  to 
t r e a t  m e l a n o m a  p a t i e n t s ,  a n d  i t s  u s e  i s  b e i n g  e v a l u a t e d  i n  
treating autoimmune and other inflammatory diseases and as 
adjuvants for vaccines. A major obstacle to more effective use 
of the CD137 pathway in clinical use is that we still do not 
completely  understand  the  mechanisms  of  CD137-mediated 
immune suppression and immune stimulation. In addition, bi-
directional signaling complicates the biology of the CD137 re-
ceptor/ligand system. It is urgent that we should define which 
activities  are  mediated  by  CD137  and  which  by  CD137L. 
Development of tools to specifically block CD137 or CD137L 
signals will be of great help in clarifying this issue. A partic-
ularly  challenging  question  is  how  CD137/CD137L  inter-
actions  simultaneously  enhance  inflammation  and  T-cell 
immunity. I suggest that signals delivered through CD137L or 
CD 1 37 L p ro te in  it se lf  ma y p lay  a c ri ti ca l ro le  in  am pl ify in g 
inflammation such a way that CD137L signals induce the pro-
duction of proinflammatory cytokines and chemokines, prob-
ably  in  synergy  with  TLR  signals  and  by  triggering  de-
granulation of granulocytes and other myeloid cells (Fig. 1). 
Inflammation amplified by CD137L in turn may contribute to 
enhancement of T cell activities together with CD137 signals 
by increasing expression levels of other costimulatory mole-
cules, MHC, cell adhesion molecules, and cytokines in anti-
gen-presenting  cells.  Thus,  CD137/CD137  interactions  form 
an  mutually  amplifying  loop  of  inflammation  and  T-cell 
immunity. It is expected that future studies will form a new 
p a r a d i g m  f o r  t h e  b i o l o g y  o f  C D 1 3 7 / C D 1 3 7 L .  
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